893 filings
6-K
ONCY
Oncolytics Biotech, Inc.
9 Dec 20
Oncolytics and SOLTI Report Clinical Synergy of Pelareorep with Checkpoint Inhibitors at the 2020 San Antonio Breast Cancer Symposium
10:22am
SUPPL
ONCY
Oncolytics Biotech, Inc.
4 Dec 20
Supplemental materials (foreign)
5:25pm
6-K
ONCY
Oncolytics Biotech, Inc.
19 Nov 20
Oncolytics Biotech® Announces Positive Clinical Results Against Glioblastoma Multiforme at the 2020 Society of Neuro-Oncology Annual Meeting
12:25pm
6-K
ONCY
Oncolytics Biotech, Inc.
17 Nov 20
Current report (foreign)
5:09pm
6-K
ONCY
Oncolytics Biotech, Inc.
12 Nov 20
Oncolytics Biotech® Reports 2020 Third Quarter Development Highlights and Financial Results
9:26am
6-K
tk3bk54my2ksu7vgdg
12 Nov 20
Interim Consolidated Financial Statements
6:15am
6-K
40areu1 7w
9 Nov 20
Current report (foreign)
11:23am
6-K
ee7d5i
9 Nov 20
Oncolytics Biotech® Announces Abstract Publication and Upcoming Oral Presentation at the 2020 Society of Neuro-Oncology Annual Meeting
10:48am
6-K
213m6e
27 Oct 20
Multi-center trial to assess the safety and efficacy of pelareorep-atezolizumab combination therapies across multiple GI cancer indications
8:59am
6-K
w0zsou5ron7tvn47w
19 Oct 20
Oncolytics Biotech® Appoints Richard Vile, Ph.D., to its Scientific Advisory Board
10:36am
6-K
x0ix 3z0bnmmh
26 Aug 20
Current report (foreign)
10:14am
6-K
d7h9r4alegox0x0q4
4 Aug 20
Oncolytics Biotech® Reports 2020 Second Quarter Financial Results and Operational Highlights
4:56pm
6-K
8jprj
4 Aug 20
Interim Consolidated Financial Statements
4:35pm
6-K
7tbfky7 ixeqld3r
25 Jun 20
Current report (foreign)
10:48am
SUPPL
e1kksi mw
25 Jun 20
Supplemental materials (foreign)
12:00am
6-K
yi1lxh0
25 Jun 20
Current report (foreign)
12:00am
6-K
602vaeeh
23 Jun 20
Current report (foreign)
12:35pm
6-K
20g7rq6n1rjtkyhnbkl
17 Jun 20
Current report (foreign)
12:00am
EFFECT
7fh7f
16 Jun 20
Notice of effectiveness
12:15am
SUPPL
e1eaqzywvpzlqz4l
16 Jun 20
Supplemental materials (foreign)
12:00am